Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT02893397 for Malignant Bone Neoplasm is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
M.D. Anderson Cancer CenterSupervised Exercise in Improving Physical Fitness Before Surgery in Patients With Resectable Bone Cancer
I. To determine if regular exercise, which may improve delivery and efficacy of chemotherapy, is feasible in children and young adults with malignant bone tumors undergoing neoadjuvant chemotherapy.
SECONDARY OBJECTIVES:
I. To determine if exercise results in a change in tumor vascularity as evidenced by magnetic resonance imaging (MRI) in children and young adults with malignant bone tumors who participate in structured aerobic exercise as compared to children and young adults who do not.
II. To determine whether serum levels of thrombospondin-1, an endogenous anti-angiogenic protein, and sphingosine-1-phosphate, an angiogenic modulator, increase in children and young adults with malignant bone tumors who participate in supervised aerobic exercise over a 4 week period of time during neoadjuvant chemotherapy.
III. To determine if aerobic exercise decreases reactive oxygen species (ROS) in the peripheral blood of bone sarcoma patients.
IV. To determine if the numbers of circulating tumor cells decrease in patients who participate in supervised exercise over a 4 week period of time.
V. To determine whether a home-based exercise program or supervised exercise program is more feasible for this patient population.
OUTLINE: Patients are assigned to 1 of 2 groups.
GROUP I: Patients wear a fitbit and undergo supervised physical therapy exercise sessions over 40 minutes 3-5 times a week for at least 4 weeks.
GROUP II: Patients wear a fitbit.
Pre-Surgical Supervised Exercise for Bone Cancer Patients
- 2016-0411
- NCI-2016-01969 (Registry Identifier) (CTRP (Clinical Trial Reporting Program))
- 2016-0411 (Other Identifier) (M D Anderson Cancer Center)
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalGroup I (supervised exercise) Patients wear a fitbit and undergo supervised physical therapy exercise sessions over 40 minutes 3-5 times a week for at least 4 weeks. | Exercise Intervention Undergo supervised exercise sessions |
ExperimentalGroup II (fitbit) Patients wear a fitbit. | Activity Monitor Wear a fitbit |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Feasibility defined as at least 10 of out 15 patients in the supervised exercise group complete more than or equal to 75% (9 of 12 sessions) supervised physical therapy exercise sessions | Completion of daily exercise is defined as at least 20 minutes of aerobic exercise achieved within heart rate and blood pressure that the licensed physical therapist has determined is safe for the patient on that given day. | At least 4 weeks |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Change in tumor vascularity as measured by magnetic resonance imaging diffusion studies | Will use a two-sided t-test with a significance level of 5% to compare the tumor vascularity between groups. | Baseline up to 4 weeks |
Change in tumor vascularity as measured by blood serum analysis of serum thrombospondin-1 and sphingosine-1-phosphate | Will use a two-sided t-test with a significance level of 5% to compare the tumor vascularity between groups. | Baseline up to 4 weeks |
- Patients must have a new diagnosis of primary bone tumor, and whose treatment plan includes surgery
- Patients who are expected to receive at least 4 weeks of neoadjuvant chemotherapy treatment between enrollment in the study and planned surgery
- Participants willing to wear a Fitbit
- Patients who are not receiving their primary cancer care (surgery and chemotherapy) at MD Anderson Cancer Center (participants from the supervised exercise group only)
- Patients who have a cognitive disorder which impacts the ability to follow directions or adhere to safety rules; this will be determined by the physical therapist by assessing whether a neurological disorder or musculoskeletal disorder would prevent the patient from safely exercising
- Patients who have a neurological or structural disorder which would impact use of exercise equipment; this will be determined by the physical therapist by assessing whether a neurological disorder or musculoskeletal disorder would prevent the patient from safely exercising
- Any patient who, in the opinion of the investigators, will be unable to comply with a supervised exercise regimen
- Any concurrent co-morbid illness and/or infection which in the opinion of the investigators could make the patient unable to comply fully with the trial procedures
M.D. Anderson Cancer Center1128 active trials to exploreNational Cancer Institute (NCI)3028 active trials to exploreTexas